Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2020184

Analysis of the Anticoagulant Market

Description:
The U.S. anticoagulant market is on the verge of a potential major shift in clinical practice, from a market dominated by a single injectable anticoagulant to a highly competitive market dominated by first-in-class novel oral anticoagulants. While these novel oral agents are expected to become standard of care for stroke prevention in atrial fibrillation patients, injectable agents will likely maintain their hold on certain hospital-based critical care applications. This research service covers the U.S. anticoagulant market from 2008 to 2016, with 2010 as the base year. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers and restraints are identified and assessed.

This Frost & Sullivan research service titled Analysis of the Anticoagulant Market provides an overview of industry trends and marketed product revenue forecasts. The study includes a complete analysis of key market drivers, restraints, and challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the following segments: oral (VKAs, factor Xa inhibitors, and direct thrombin inhibitors) and parenteral (indirect thrombin inhibitors, and direct thrombin inhibitors).


Market Overview

Large Atrial Fibrillation Population with Unmet Needs Will Help the U.S. Anticoagulant Market to Grow to $10 billion by 2016

Rollout of Novel Oral Anticoagulants Poised to Drastically Change the Clinical Practice Landscape

The U.S. anticoagulant market is on the verge of a major shift in clinical practice. It is transitioning from a market dominated by a single injectable anticoagulant to a highly competitive one dominated by first-in-class novel oral anticoagulants. Companies are vying with each other to introduce novel therapies that offer superior safety, efficacy, and convenience to patients and physicians. This is a medical need that has been unmet for decades. “Studies reveal that there are currently 2.7 million patients in the United States with atrial fibrillation (AF); however, this may be an underestimation as the actual figure could be as high as 4.0 million,” notes the analyst of this research service. “Lifelong anticoagulant therapy is critical for stroke prevention in these patients, resulting in substantial commercial opportunities.” Warfarin, the long-established gold standard therapy for stroke prevention in AF, carries many significant inherent risks such as bleeding, leaving a very narrow therapeutic window.

A robust growth period is expected following the launch of Pradaxa (dabigatran), an oral direct thrombin inhibitor (DTI) in late 2010, followed by a second growth period upon the anticipated launch of Eliquis (apixaban), an oral factor Xa inhibitor in late 2012 or early 2013. Edoxaban, an oral factor Xa inhibitor is also in the pipeline, and Xarelto (rivaroxaban), another oral factor Xa inhibitor which is approved for prophylaxis following orthopedic surgery, is awaiting approval for stroke prevention. These agents are poised to dominate the market for stroke prevention in AF, a very large and partially untapped market. They are also likely to grab substantial market share from the parenteral anticoagulants for prophylaxis of venous thromboembolism in orthopedic joint replacement surgery. With the approval of Pradaxa and the imminent approval of its successors, the bar has been significantly raised for the anticoagulant market. Superiority to warfarin is paramount for new drug approval and market uptake. Patient and clinician acceptance will depend on strong data showing improvements in efficacy and lower risk of bleeding.

There is a fine line between the prevention of thrombosis and uncontrollable bleeding. Most often, bleeding issues or other safety concerns may not arise until late-stage clinical trials, or only in certain patient populations, after significant investments in drug development have been made. In addition, bleeding issues or other safety concerns may surface in the future, particularly if the bleeding risk of the real-world population differs from that studied in clinical trials, leading to black-box warnings or market withdrawal.

One of the shortcomings of oral anticoagulants is the lack of a strategy for reversal in case of emergency or uncontrolled bleeding. “The oral anticoagulants are ideal for chronic therapy with their easy administration,” says the analyst. “However, the ability to quickly reverse the anticoagulant action in the event of an emergency is a critical unmet need.” Newcomers to the market that can address this issue will resolve the key shortfall of chronic anticoagulation therapy and their drugs are likely see rapid adoption into clinical practice.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

- Oral (VK, factor Xa inhibitors, direct thrombin inhibitors)
- Parenteral (indirect thrombin inhibitors, and direct thrombin inhibitors

Technologies

The following technologies are covered in this research:

- Subcutaneous injection
- Oral administration
- Intravenous administration
- Coagulation monitoring
 
Contents:
1. Executive Summary

2. Market Overview

3. Total Market
3.1 External Challenges: Drivers and Restraints
3.2 Forecasts and Trends
3.3 Demand Analysis
3.4 Market Share and Competitive Analysis

4 Parenteral Anticoagulant Segment Breakdown

5. Oral Anticoagulant Segment Breakdown

6. The Last Word (Conclusions and Implications)

7. Appendix
71. Relevant KOL Commentary
7.2 Product Level Market Share Analysis
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2020184

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 20th 2014
5:59:04 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Analysis of the Anticoagulant Market

Web Address

http://www.researchandmarkets.com/reports/2020184

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License USD 6,000
Electronic (PDF) - Enterprisewide USD 7,500
Electronic and Hard Copy (PDF) - Site License USD 6,500 + USD 66 Shipping/Handling *
Electronic and Hard Copy (PDF) - Enterprisewide USD 8,000 + USD 66 Shipping/Handling *

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 20th 2014
5:59:04 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)